TABLE 1.
Location of Pediatric Subjects in Clinical Trials 2002–2007
| Patient No. (%) |
|
|---|---|
| Cardiovascular trials (N = 1539)a | |
| Developed countriesb | |
| United States | 798 (51) |
| Netherlands | 398 (26) |
| Canada | 61 (4) |
| Hungary | 36 (2) |
| Norway | 35 (2) |
| New Zealand | 16 (1) |
| Developing/transition countriesb | |
| South Africa | 53 (3) |
| Argentina | 22 (1) |
| Chile | 20 (1) |
| Russia | 20 (1) |
| Brazil | 16 (1) |
| Peru | 11 (1) |
| Juvenile rheumatoid arthritis trials (N = 556) | |
| Developed countriesb | |
| United States | 180 (32) |
| Israel | 52 (9) |
| Germany | 42 (8) |
| Australia | 42 (8) |
| Norway | 30 (5) |
| Austria | 22 (4) |
| Portugal | 21 (4) |
| Italy | 9 (2) |
| Developing/transition countriesb | |
| Peru | 47 (8) |
| Argentina | 42 (8) |
| Brazil | 40 (7) |
| Mexico | 21 (4) |
| Chile | 8 (1) |
a
Cardiovascular conditions studied included hypertension, heart failure, arrhythmia, and heterozygous familial hypercholesterolemia.
b
This delineation is subjective and based on a United Nations reference that indicates that the delineation is not an established convention and should be viewed as a generalization.